DB05089ExperimentalVaccines
VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ). Interferon-γ... Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells.
- Primary indication
- Investigated for use/treatment in prostate cancer.Curator reviewed
- Code names
- VPM4001
Which companies are running trials of VPM4001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account